Satellos Bioscience clinical trials we track

Check company identity source

Phase 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 24 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 24 months. After: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 12 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 12 months.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Treatment emergent adverse events. After: Measure: Treatment emergent adverse events Measure: SAT-3247 effect on fat fraction in biceps brachii.

Planned enrollment increased by 20 participants

Before: 10 participants (planned). After: 30 participants (planned).

Primary completion date changed

Before: 30 Aug 2026. After: 30 Sep 2027.

Check registry source